GHRP-6

GHRP-6

Product Overview GHRP-6 acts as a robust secretagogue, stimulating the anterior pituitary gland to release natural Growth Hormone (GH). As a selective agonist of the ghrelin/growth hormone receptor, it belongs to a specialized class of ghrelin analogues developed to target specific metabolic and regenerative pathways. Clinical research suggests GHRP-6 possesses significant therapeutic potential in cardiac muscle preservation, memory consolidation, wound healing, libido regulation, and neuroprotection in Parkinson’s disease models. The peptide demonstrates activity via oral and sublingual administration with distinct selectivity.

Primary Research Effects

1. Enhancement of Memory and Cognition Scientific inquiry into the link between physical exertion and cognitive retention has highlighted the role of growth hormone secretagogues. While physical activity is known to aid learning, particularly immediately following a task, recent rodent studies suggest GHRP-6 mediates this process. The peptide appears to facilitate the solidification of memory, effectively converting short-term inputs into long-term storage. Furthermore, evidence regarding spatial learning suggests that the cognitive benefits often attributed to GH are likely secondary to the signaling of peptides like GHRP-6.

2. Neuroprotection and Stroke Recovery In animal models focusing on ischemic stroke, GHRP-6 has demonstrated the capacity to shield neurons and central nervous system cells from damage caused by restricted blood flow. Beyond acute protection, timely administration of the peptide has been observed to rescue memory deficits post-stroke. The mechanism appears to be the inhibition of apoptosis (programmed cell death) and the reduction of neuroinflammation, thereby preserving neuronal integrity against both genetic and environmental stressors.

3. Potential in Parkinson’s Disease Management Research regarding the ghrelin receptor density in the brain's portal areas has shed light on GHRP-6’s potential utility in Parkinson’s disease. Studies have identified a correlation between decreased ghrelin receptor expression in the substantia nigra and the onset of motor dysfunction. By binding to these diminished receptors, GHRP-6 may reduce neuronal apoptosis, potentially slowing the progression of Parkinsonian symptoms and offering a neuroprotective buffer in affected subjects.

4. Dermal Healing and Scar Mitigation GHRP-6 promotes cell viability and accelerates angiogenesis (new blood vessel formation), particularly within wounded tissue. In rat models, these properties have proven effective for treating burns and speeding up wound closure. By optimizing the deposition of extracellular matrix proteins like collagen, the peptide enhances the mechanical strength of the healed tissue while minimizing aesthetic defects. Notably, GHRP-6 helps prevent the formation of hypertrophic scars and keloids, offering a potential solution for managing abnormal scarring that restricts movement or causes pain.

5. Cardioprotective Capabilities In porcine studies of myocardial infarction, GHRP-6 treatment has been shown to mitigate oxidant cytotoxicity. The peptide limits the tissue damage typically caused by reperfusion (the restoration of blood flow) following a heart attack. This protective effect is crucial for preserving vulnerable but viable heart muscle cells, which may reduce mortality risks and improve long-term cardiac function post-infarction.

6. Modulation of Libido and Mood Investigations involving male rats suggest that central nervous system ghrelin receptors play a key role in sexual behavior. Elevated ghrelin activity correlates with increased sexual motivation, a specific effect replicated by GHRP-6 and its analogue, GHRP-2. Beyond libido, these receptors modulate reward-seeking behaviors and mood. Murine studies indicate that ghrelin analogues can alleviate depressive symptoms and anxiety, particularly under stress, suggesting potential applications in treating mood disorders.

Product Specifications & Disclaimer GHRP-6 is characterized by minimal side effects and possesses excellent subcutaneous bioavailability in mice, though oral bioavailability is lower. Important: Dosage data derived from animal models does not directly correlate to human physiology. GHRP-6 sold by Peptide Sciences is strictly for educational and scientific research purposes and is not intended for human consumption. Purchase is restricted to licensed research professionals.

Editorial Author The technical literature provided above was compiled and edited by Dr. Logan, M.D. Dr. Logan earned his doctorate from Case Western Reserve University School of Medicine and holds a B.S. in Molecular Biology.

Scientific Reference Marta Korbonits, M.D., PhD, is a distinguished Professor of Endocrinology and Metabolism at Queen Mary University of London. Following her medical graduation in Budapest and early training at St. Bartholomew's Hospital, she has made significant contributions to the field of endocrinology. Her work has elucidated the mechanisms of growth hormone secretagogues, hypothalamic regulation, and the ghrelin axis. She is also credited with identifying AIP gene mutations and discovering new pathways in glucocorticoid metabolic regulation. Professor Korbonits currently serves as a leader at the William Harvey Research Institute.

Dr. Marta Korbonits is cited here solely to acknowledge her foundational role in the research of GHRP-6. She has no affiliation with Peptide Sciences and does not endorse the sale or use of this product.

References

1. C.-C. Huang, et al., "Acute food deprivation enhances fear extinction but inhibits long-term depression in the lateral amygdala via ghrelin signaling," Neuropharmacology, vol. 101, pp. 36–45, Feb. 2016.
2. S. Beheshti and S. Shahrokhi, "Blocking the ghrelin receptor type 1a in the rat brain impairs memory encoding," Neuropeptides, vol. 52, pp. 97–102, Aug. 2015.
3. K. Tóth, et al., "Role of intraamygdaloid acylated-ghrelin in spatial learning," Brain Res. Bull., vol. 81, no. 1, pp. 33–37, Jan. 2010.
4. N. Sucháč et al., "Assessment of dose-effect and therapeutic time window in preclinical studies of nIGF-1 and GHRP-6 coadministration for stroke therapy," Neurol. Res., vol. 38, no. 3, pp. 187–195, Mar. 2016.
5. S. J. Spencer, A. A. Miller, and Z. B. Andrews, "The Role of Ghrelin in Neuroprotection after Ischemic Brain Injury," Brain Sci., vol. 3, no. 1, pp. 344–359, Mar. 2013.
6. Y. Sutra et al., "Down-regulation of ghrelin receptors on dopaminergic neurons in the substantia nigra contributes to Parkinson's disease-like motor dysfunction," Mol. Brain., vol. 11, no. 1, p. 6, 2018.
7. Y. Mendoza-Mari et al., "Growth Hormone-Releasing Peptide-6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wound," Plastic Surgery International, 2016.
8. M. Fernández-Mayola et al., "Growth hormone releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study," Int. Wound J., vol. 15, no. 4, pp. 538–546, Aug. 2018.
9. J. Berlanga et al., "Growth hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction," Clin. Sci., vol. 112, no. 4, pp. 241–250, Feb. 2007.
10. L. Hyland et al., "Central ghrelin receptor stimulation modulates sex motivation in male rats in a site dependent manner," Horm. Behav., vol. 97, pp. 56–66, 2018.
11. H. J. Huang et al., "The protective effects of Ghrelin/GHSR on hippocampal neurogenesis in CUMS mice," Neuropharmacology, May 2019.
12. Korbonits, Marta, and Ashley B. Grossman. "Growth Hormone-Releasing Peptide and Its Analogues." Trends in Endocrinology & Metabolism, vol. 6, no. 2, Mar. 1995, pp. 43–49.